LUAD LUSC

LUAD LUSC analyzes TCGA-derived next-generation sequencing and multi-omics data to identify genomic signatures and signaling pathways that distinguish Lung Adenocarcinoma (LUAD) from Squamous Cell Carcinoma (LUSC).

Key Features:

• Data Integration and Analysis: Integrates next-generation sequencing and TCGA multi-omics data from over 1,000 LUAD and LUSC patients using a robust statistical framework and diverse bioinformatic tools to address inter-tumor heterogeneity.
• Gene Expression Profiling: Identifies co-expression modules and differentially expressed genes to pinpoint subtype-specific oncogenes, tumor suppressors, and genes with dual roles across LUAD and LUSC.
• Validation: Validates findings against additional lung cancer transcriptomics datasets.
• LUAD signature: Highlights substantial up-regulation of genes involved in O-glycosylation of mucins as a distinctive molecular signature of LUAD.
• LUSC signature: Detects a compromised immune response associated with activation of oncogenic pathways that facilitate antitumor immune evasion in LUSC.

Scientific Applications:

• Molecular characterization: Dissects molecular underpinnings of LUAD and LUSC to reveal subtype-specific genetic and signaling alterations.
• Therapeutic development: Informs targeted therapy strategies by distinguishing genetic alterations and immune profiles specific to each lung cancer subtype.

Methodology:

The methodology uses a comprehensive integrative approach that combines robust statistical analysis with bioinformatic tools to dissect complex genomic data.